CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The US Department of Health and Human Services is to cancel contracts and pull funding for some vaccines that are being ...

The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...

With a market cap of $10.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of ...

The targeting of the vaccine technology once considered revolutionary follows intense criticism by conservatives and anti-vaccine activists.

The tide is turning in America’s COVID policy, with the recent announcement that the federal government will no longer recommend booster shots for most healthy Americans under the age of 65. This ...